Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jul 6;8:777. doi: 10.3389/fimmu.2017.00777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Lomakin, Arapidi, Chernov, Ziganshin, Tcyganov, Lyadova, Butenko, Osetrova, Ponomarenko, Telegin, Govorun, Gabibov and Belogurov.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Myelin-reactive antibodies are induced in vivo upon immunization with viral antigen. (A) Immunization schemes representing chronic immune response (CIR) and multiple acute subsequent immunization (MASI) models. Timeline indicates immunizations (designated by roman numbers and arrows) and blood sample collection from vena ophthalmica (designated by white rhombs). (B) Analysis of presence of anti-myelin basic protein (MBP) (top), anti-LMP (middle), and anti-ovalbumin (OVA) (bottom) antibodies in serum of BALB/c and SJL mice immunized with MBP (blue line), latent membrane protein 1 (LMP1) (red line), or OVA (black dashed line) according to CIR (left) or MASI (right) model. Data represent average and SD. Asterisk denotes statistically significant difference of anti-MBP and anti-LMP1 antibody titer in serum of MBP- or LMP1-immunized mice in comparison with a control (OVA-immunized mice) or anti-OVA antibody titer in serum of OVA-immunized mice in comparison with a control with a MBP- and LMP1-immunized mice.